产品
编 号：F026627
分子式：C8H15NaO2
分子量：166.19
分子式：C8H15NaO2
分子量：166.19
产品类型
规格
价格
是否有货
500mg
280
In-stock
1g
360
In-stock
5g
640
In-stock
25g
800
In-stock
结构图
CAS No: 1069-66-5
产品详情
生物活性：
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
体内研究：
Valproic acid (VPA) (500 mg/kg; i.p.; daily for 12 days) inhibits tumor angiogenesis in mice transplanted with Kasumi-1 cells.Valproic acid (350 mg/kg; i.p.; once) enhances social behavior in rats.Valproic acid (0.26% (w/v); p.o. via drinking water; 14 days) decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice without hepatotoxicity.Animal Model:Female BALB/c nude mice, Kasumi-1 tumor model
Dosage:500 mg/kg
Administration:Intraperitoneal injection, daily for 12 days
Result:Inhibited tumor growth and tumor angiogenesis.Inhibited the mRNA and protein expression of VEGF, VEGFR2 and bFGF.Inhibited HDAC activity and increased acetylation of histone H3.Enhanced the accumulation of hyperacetylated histone H3 on VEGF promoters.
Animal Model:Timed-pregnant Long Evans rats
Dosage:350 mg/kg
Administration:Intraperitoneal injection, once
Result:Demonstrated more social investigation and play fighting than control animals.
Animal Model:Obese phenotype of ob/ob mice
Dosage:0.26% (w/v)
Administration:Oral via drinking water, 14 days
Result:Revealed a marked reduction in the accumulation of fats in the liver as compared with the untreated mice, significantly decreased liver mass to body mass, decreased serum triglyceride concentrations, and did not induce hepatotoxicity.
体外研究：
Valproic acid (VPA) (0-15 mM; 24 and 72 h) inhibits Hela cell growth in a dose- and time- dependent manner.Valproic acid (10 mM; 24 h) significantly attenuates the activities of total, cytosol and nuclear HDACs.Valproic acid (0-15 mM; 24 h) induces a G1 phase arrest at 1–3 mM and a G2/M phase arrest at 10 mM, and increases the percentage of sub-G1 cells in HeLa cells. Valproic acid also induces necrosis, apoptosis and lactate dehydrogenase (LDH) release.Valproic acid (0-20 mM; 24 h) activates Tcf/Lef-dependent transcription and synergizes with lithium.Valproic acid (0-5 mM; 0-18 h) increases β-catenin levels in Neuro2A cells.Valproic acid (0-2 mM; 0-24 h) stimulates phosphorylation of AMPK and ACC in hepatocytes.Valproic acid (0-10 mM; 2 days) induces Notch1 signaling and morphologic differentiation, suppresses production of NE tumor markers in SCLC cells.
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
体内研究：
Valproic acid (VPA) (500 mg/kg; i.p.; daily for 12 days) inhibits tumor angiogenesis in mice transplanted with Kasumi-1 cells.Valproic acid (350 mg/kg; i.p.; once) enhances social behavior in rats.Valproic acid (0.26% (w/v); p.o. via drinking water; 14 days) decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice without hepatotoxicity.Animal Model:Female BALB/c nude mice, Kasumi-1 tumor model
Dosage:500 mg/kg
Administration:Intraperitoneal injection, daily for 12 days
Result:Inhibited tumor growth and tumor angiogenesis.Inhibited the mRNA and protein expression of VEGF, VEGFR2 and bFGF.Inhibited HDAC activity and increased acetylation of histone H3.Enhanced the accumulation of hyperacetylated histone H3 on VEGF promoters.
Animal Model:Timed-pregnant Long Evans rats
Dosage:350 mg/kg
Administration:Intraperitoneal injection, once
Result:Demonstrated more social investigation and play fighting than control animals.
Animal Model:Obese phenotype of ob/ob mice
Dosage:0.26% (w/v)
Administration:Oral via drinking water, 14 days
Result:Revealed a marked reduction in the accumulation of fats in the liver as compared with the untreated mice, significantly decreased liver mass to body mass, decreased serum triglyceride concentrations, and did not induce hepatotoxicity.
体外研究：
Valproic acid (VPA) (0-15 mM; 24 and 72 h) inhibits Hela cell growth in a dose- and time- dependent manner.Valproic acid (10 mM; 24 h) significantly attenuates the activities of total, cytosol and nuclear HDACs.Valproic acid (0-15 mM; 24 h) induces a G1 phase arrest at 1–3 mM and a G2/M phase arrest at 10 mM, and increases the percentage of sub-G1 cells in HeLa cells. Valproic acid also induces necrosis, apoptosis and lactate dehydrogenase (LDH) release.Valproic acid (0-20 mM; 24 h) activates Tcf/Lef-dependent transcription and synergizes with lithium.Valproic acid (0-5 mM; 0-18 h) increases β-catenin levels in Neuro2A cells.Valproic acid (0-2 mM; 0-24 h) stimulates phosphorylation of AMPK and ACC in hepatocytes.Valproic acid (0-10 mM; 2 days) induces Notch1 signaling and morphologic differentiation, suppresses production of NE tumor markers in SCLC cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备